Galiximab

Drug Profile

Galiximab

Alternative Names: IDEC 114; IDEC 114-20

Latest Information Update: 08 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD80 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Autoimmune disorders; Non-Hodgkin's lymphoma; Psoriasis

Most Recent Events

  • 04 Feb 2011 Galiximab is available for licensing as of 04 Feb 2011. www.biogenidec.com
  • 09 Dec 2008 Efficacy and adverse events data from a long-term follow up of a phase II trial in Non-Hodgkin's lymphoma presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
  • 30 Jan 2007 Discontinued - Phase-II for Autoimmune disorders in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top